首页> 外文期刊>Journal of Controlled Release: Official Journal of the Controlled Release Society >An amphipathic alpha-helical peptide from apolipoprotein A1 stabilizes protein polymer vesicles
【24h】

An amphipathic alpha-helical peptide from apolipoprotein A1 stabilizes protein polymer vesicles

机译:来自载脂蛋白A1的两亲性α螺旋肽可稳定蛋白质聚合物囊泡

获取原文
获取原文并翻译 | 示例
           

摘要

L4F, an alpha helical peptide inspired by the lipid-binding domain of the ApoA1 protein, has potential applications in the reduction of inflammation involved with cardiovascular disease as well as an antioxidant effect that inhibits liver fibrosis. In addition to its biological activity, amphipathic peptides such as L4F are likely candidates to direct the molecular assembly of peptide nanostructures. Here we describe the stabilization of the amphipathic L4F peptide through fusion to a high molecular weight protein polymer. Comprised of multiple pentameric repeats, elastin-like polypeptides (ELPs) are biodegradable protein polymers inspired from the human gene for tropoelastin. Dynamic light scattering confirmed that the fusion peptide forms nanoparticles with a hydrodynamic radius of approximately 50 nm, which is unexpectedly above that observed for the free ELP (~5.1 nm). To further investigate their morphology, conventional and cryogenic transmission electron microscopy were used to reveal that they are unilamellar vesicles. On average, these vesicles are 49 nm in radius with lamellae 8 nm in thickness. To evaluate their therapeutic potential, the L4F nanoparticles were incubated with hepatic stellate cells. Stellate cell activation leads to hepatic fibrosis; furthermore, their activation is suppressed by anti-oxidant activity of ApoA1 mimetic peptides. Consistent with this observation, L4F nanoparticles were found to suppress hepatic stellate cell activation in vitro. To evaluate the in vivo potential for these nanostructures, their plasma pharmacokinetics were evaluated in rats. Despite the assembly of nanostructures, both free L4F and L4F nanoparticles exhibited similar half-lives of approximately 1 h in plasma. This is the first study reporting the stabilization of peptide-based vesicles using ApoA1mimetic peptides fused to a protein polymer; furthermore, this platform for peptide-vesicle assembly may have utility in the design of biodegradable nanostructures.
机译:L4F是一种受ApoA1蛋白的脂质结合域启发的α螺旋肽,在减少与心血管疾病有关的炎症以及抑制肝纤维化的抗氧化作用方面具有潜在的应用前景。除了其生物活性外,两亲性肽(例如L4F)可能是指导肽纳米结构分子组装的候选物。在这里,我们描述了通过融合至高分子量蛋白质聚合物来稳定两亲性L4F肽的方法。弹性蛋白样多肽(ELPs)由多个五聚体重复组成,是可生物降解的蛋白质聚合物,受到人类弹性蛋白原基因的启发。动态光散射证实融合肽形成的纳米颗粒的流体力学半径约为50 nm,这出乎意料地高于游离ELP(〜5.1 nm)观察到的流体动力学半径。为了进一步研究其形态,常规和低温透射电子显微镜被用来揭示它们是单层囊泡。这些囊泡的平均半径为49 nm,层厚为8 nm。为了评估其治疗潜力,将L4F纳米颗粒与肝星状细胞一起孵育。星状细胞活化导致肝纤维化。此外,它们的活化被ApoA1模拟肽的抗氧化活性抑制。与该观察结果一致,发现L4F纳米颗粒在体外抑制肝星状细胞活化。为了评估这些纳米结构的体内潜力,在大鼠中评估了它们的血浆药代动力学。尽管组装了纳米结构,游离的L4F和L4F纳米颗粒在血浆中均表现出相似的大约1小时的半衰期。这是第一项报道使用与蛋白质聚合物融合的ApoA1模拟肽稳定基于肽的囊泡的研究。此外,该用于肽-小泡组装的平台可在设计可生物降解的纳米结构中具有实用性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号